Floraworks Holdings, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Floraworks Holdings, Inc. - overview
Established
2019
Location
Milwaukie, OR, US
Primary Industry
Biotechnology
About
Based in Oregon, US, and founded in 2019, FloraWorks Holdings Inc. operates as a biotechnology company specializing in cannabinoids for medical needs. In December 2022, the firm raised its series A funding led by investor Bonaventure Capital. The company as of December 2022 is led by its CEO, Alan Ridgeway.
The company offers cannabinoid isolation through proprietary refinement methods, specialized formulation, and product development for client’s products and therapeutic medicine including cannabinoids as an ingredient, technical expertise in quality assurance, and regulatory guidance for therapeutic medicine. The company plans to utilize its December 2022 funding to further develop its cannabinoid therapeutics for people.
Current Investors
Bonaventure Capital, ArcView Group
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Alternative Medicine
Website
www.flora-works.com
Verticals
Cannabis/Medical Marijuana, Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.